Screener
TG Therapeutics TGTX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | (2,453) | (2,733) | (3,039) | (3,141) |
| Net income | $7,781 | $28,187 | $27,558 | $33,247 |
| Net income per common share: | ||||
| Basic | $0.05 | $0.19 | $0.19 | $0.23 |
| Diluted | $0.05 | $0.17 | $0.17 | $0.20 |
| Weighted-average shares of common stock outstanding | ||||
| Basic | 141,770,283 | 146,739,833 | 143,097,453 | 146,708,980 |
| Diluted | 157,281,850 | 162,559,404 | 158,664,407 | 162,528,551 |
Document
FAQ
- What is TG Therapeutics's shares (diluted)?
- TG Therapeutics (TGTX) reported shares (diluted) of 157.3M in Q2 2026.
- How has TG Therapeutics's shares (diluted) changed year-over-year?
- TG Therapeutics's shares (diluted) decreased by 3.2% year-over-year, from 162.6M to 157.3M.
- What is the long-term trend for TG Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), TG Therapeutics's shares (diluted) has grown at a 5.2% compound annual growth rate (CAGR), from 528.5M to 647.7M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about TG Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude